Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy.
Osteopontinspiegel im Plasma bei dilatativer und hypertrophischer Kardiomyopathie.
Cardiomyopathies
Extracellular matrix glycoprotein
Heart failure
Myocardium
Ventricular remodeling
Journal
Herz
ISSN: 1615-6692
Titre abrégé: Herz
Pays: Germany
ID NLM: 7801231
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
20
08
2017
accepted:
22
10
2017
revised:
16
10
2017
pubmed:
18
11
2017
medline:
8
10
2019
entrez:
18
11
2017
Statut:
ppublish
Résumé
Osteopontin (OPN) is an extracellular matrix glycoprotein that plays a role in a variety of cellular activities associated with inflammatory and fibrotic responses. Increased OPN levels in myocardium and plasma have been demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). Therefore, the aim of our study was to compare plasma OPN levels in patients with these two most common cardiomyopathies. We examined plasma OPN as well as creatinine, C‑reactive protein (CRP), brain-type natriuretic peptide (BNP), and troponin I levels in 64 patients with DCM, 43 patients with HCM, and 75 control subjects. Transthoracic echocardiography was also performed on all cardiomyopathy patients. Plasma OPN levels were significantly elevated in patients with DCM compared with HCM patients (95 ± 43 vs. 57 ± 21 ng/ml; p < 0.001) and control subjects (54 ± 19 ng/ml; p < 0.001); however, there was no difference between HCM patients and control subjects. New York Heart Association (NYHA) class III or IV disease was more frequently present in DCM patients than in HCM subjects (44 % vs. 2 %, p < 0.0001). In multivariate analysis, BNP and CRP levels together with NYHA class were found to be significant predictors of plasma OPN levels in DCM patients (p = 0.002, p = 0.029, and p < 0.001 for BNP, CRP, and NYHA, respectively). Plasma OPN levels were associated with overall heart failure severity rather than with specific cardiomyopathy subtype in patients suffering from DCM or HCM, respectively.
Sections du résumé
BACKGROUND
BACKGROUND
Osteopontin (OPN) is an extracellular matrix glycoprotein that plays a role in a variety of cellular activities associated with inflammatory and fibrotic responses. Increased OPN levels in myocardium and plasma have been demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). Therefore, the aim of our study was to compare plasma OPN levels in patients with these two most common cardiomyopathies.
PATIENTS AND METHODS
METHODS
We examined plasma OPN as well as creatinine, C‑reactive protein (CRP), brain-type natriuretic peptide (BNP), and troponin I levels in 64 patients with DCM, 43 patients with HCM, and 75 control subjects. Transthoracic echocardiography was also performed on all cardiomyopathy patients.
RESULTS
RESULTS
Plasma OPN levels were significantly elevated in patients with DCM compared with HCM patients (95 ± 43 vs. 57 ± 21 ng/ml; p < 0.001) and control subjects (54 ± 19 ng/ml; p < 0.001); however, there was no difference between HCM patients and control subjects. New York Heart Association (NYHA) class III or IV disease was more frequently present in DCM patients than in HCM subjects (44 % vs. 2 %, p < 0.0001). In multivariate analysis, BNP and CRP levels together with NYHA class were found to be significant predictors of plasma OPN levels in DCM patients (p = 0.002, p = 0.029, and p < 0.001 for BNP, CRP, and NYHA, respectively).
CONCLUSION
CONCLUSIONS
Plasma OPN levels were associated with overall heart failure severity rather than with specific cardiomyopathy subtype in patients suffering from DCM or HCM, respectively.
Identifiants
pubmed: 29147972
doi: 10.1007/s00059-017-4645-3
pii: 10.1007/s00059-017-4645-3
doi:
Substances chimiques
Osteopontin
106441-73-0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-353Références
Hypertension. 1999 Feb;33(2):663-70
pubmed: 10024324
QJM. 2002 Jan;95(1):3-13
pubmed: 11834767
Eur J Heart Fail. 2002 Mar;4(2):139-46
pubmed: 11959041
J Clin Invest. 2003 Jul;112(2):147-9
pubmed: 12865402
Heart. 2004 Apr;90(4):464-70
pubmed: 15020532
Hypertension. 2004 Dec;44(6):809-10
pubmed: 15520299
Eur J Heart Fail. 2005 Aug;7(5):755-62
pubmed: 16087132
Circulation. 2005 Sep 6;112(10):1428-34
pubmed: 16129801
J Vet Med Sci. 2006 Apr;68(4):379-82
pubmed: 16679731
Heart Fail Rev. 2006 Mar;11(1):83-92
pubmed: 16819581
Heart. 2006 Oct;92(10):1514-5
pubmed: 16973806
Eur Heart J. 2008 Jan;29(2):270-6
pubmed: 17916581
Comp Med. 2007 Dec;57(6):546-53
pubmed: 18246866
J Am Coll Cardiol. 2008 Apr 8;51(14):1384-92
pubmed: 18387441
Mol Cell Biochem. 2009 Feb;322(1-2):25-36
pubmed: 18985280
Circ Res. 2009 Apr 10;104(7):851-9
pubmed: 19246678
Eur J Echocardiogr. 2009 Mar;10(2):165-93
pubmed: 19270053
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Mol Cell Cardiol. 2010 Mar;48(3):538-43
pubmed: 19573532
Circ Heart Fail. 2008 May;1(1):43-9
pubmed: 19808269
Heart Fail Rev. 2010 Sep;15(5):487-94
pubmed: 20127409
Circ Heart Fail. 2010 May;3(3):431-9
pubmed: 20200330
Semin Thromb Hemost. 2010 Mar;36(2):195-202
pubmed: 20414835
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Int J Cardiol. 2011 Dec 15;153(3):306-10
pubmed: 20863582
Immunol Res. 2011 Apr;49(1-3):160-72
pubmed: 21136203
Fa Yi Xue Za Zhi. 2012 Aug;28(4):247-51
pubmed: 23033660
Eur J Heart Fail. 2013 Dec;15(12):1390-400
pubmed: 23851388
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Life Sci. 2014 Nov 18;118(1):1-6
pubmed: 25265596
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Circ Res. 2016 Jun 24;119(1):159-76
pubmed: 27340274
Am J Cardiol. 1986 Feb 15;57(6):450-8
pubmed: 2936235
Proc Natl Acad Sci U S A. 1986 Dec;83(23):8819-23
pubmed: 3024151
J Immunol. 1999 Jan 15;162(2):1024-31
pubmed: 9916729